Literature DB >> 33753799

Moderate vs. mild cases of overseas-imported COVID-19 in Beijing: a retrospective cohort study.

Wenliang Zhai1, Zujin Luo2, Yue Zheng3, Dawei Dong4, Endong Wu5, Zhengfang Wang6, Junpeng Zhai7, Yujuan Han8, Huan Liu9, Yanran Wang10, Yaohui Feng11, Jing Wang12, Yingmin Ma13.   

Abstract

This study compared the differences in the clinical manifestations, treatment courses and clinical turnover between mild and moderate coronavirus disease 2019 (COVID-19). Clinical data of the patients with imported COVID-19 admitted to Beijing Xiaotangshan Designated Hospital between March 15 and April 30, 2020, were retrospectively analysed. A total of 53 COVID-19 patients were included, with 21 mild and 32 moderate cases. Compared with the mild group, the moderate group showed significant differences in breathing frequency, lymphocyte count, neutrophil percentage, neutrophil/lymphocyte ratio, procalcitonin, C-reactive protein, and dynamic erythrocyte sedimentation rate. In the moderate group, 87.5% exhibited ground-glass opacities, 14% exhibited consolidative opacities, 53.1% exhibited local lesions and 68.8% exhibited unilateral lesions. The proportion of patients who received antiviral or antibiotic treatment in the moderate group was higher than that in the mild group, and the number of cases that progressed to severe disease in the moderate group was also significantly higher (18.7% vs. 0%, p = 0.035). Compared with patients with mild COVID-19, those with moderate COVID-19 exhibited more noticeable inflammatory reactions, more severe pulmonary imaging manifestations and earlier expression of protective antibodies. The overall turnover of the moderate cases was poorer than that of the mild cases.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33753799      PMCID: PMC7985387          DOI: 10.1038/s41598-021-85869-0

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  40 in total

1.  Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China.

Authors:  Dawei Wang; Bo Hu; Chang Hu; Fangfang Zhu; Xing Liu; Jing Zhang; Binbin Wang; Hui Xiang; Zhenshun Cheng; Yong Xiong; Yan Zhao; Yirong Li; Xinghuan Wang; Zhiyong Peng
Journal:  JAMA       Date:  2020-03-17       Impact factor: 56.272

2.  Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China.

Authors:  Chuan Qin; Luoqi Zhou; Ziwei Hu; Shuoqi Zhang; Sheng Yang; Yu Tao; Cuihong Xie; Ke Ma; Ke Shang; Wei Wang; Dai-Shi Tian
Journal:  Clin Infect Dis       Date:  2020-07-28       Impact factor: 9.079

3.  Failure to normalize lymphopenia following trauma is associated with increased mortality, independent of the leukocytosis pattern.

Authors:  Daithi S Heffernan; Sean F Monaghan; Rajan K Thakkar; Jason T Machan; William G Cioffi; Alfred Ayala
Journal:  Crit Care       Date:  2012-01-20       Impact factor: 9.097

4.  Detection of IgM and IgG antibodies in patients with coronavirus disease 2019.

Authors:  Hongyan Hou; Ting Wang; Bo Zhang; Ying Luo; Lie Mao; Feng Wang; Shiji Wu; Ziyong Sun
Journal:  Clin Transl Immunology       Date:  2020-05-06

5.  CT Imaging Features of 2019 Novel Coronavirus (2019-nCoV).

Authors:  Michael Chung; Adam Bernheim; Xueyan Mei; Ning Zhang; Mingqian Huang; Xianjun Zeng; Jiufa Cui; Wenjian Xu; Yang Yang; Zahi A Fayad; Adam Jacobi; Kunwei Li; Shaolin Li; Hong Shan
Journal:  Radiology       Date:  2020-02-04       Impact factor: 11.105

6.  Clinical Characteristics of Imported Cases of Coronavirus Disease 2019 (COVID-19) in Jiangsu Province: A Multicenter Descriptive Study.

Authors:  Jian Wu; Jun Liu; Xinguo Zhao; Chengyuan Liu; Wei Wang; Dawei Wang; Wei Xu; Chunyu Zhang; Jiong Yu; Bin Jiang; Hongcui Cao; Lanjuan Li
Journal:  Clin Infect Dis       Date:  2020-07-28       Impact factor: 9.079

7.  COVID-19 with Different Severities: A Multicenter Study of Clinical Features.

Authors:  Yun Feng; Yun Ling; Tao Bai; Yusang Xie; Jie Huang; Jian Li; Weining Xiong; Dexiang Yang; Rong Chen; Fangying Lu; Yunfei Lu; Xuhui Liu; Yuqing Chen; Xin Li; Yong Li; Hanssa Dwarka Summah; Huihuang Lin; Jiayang Yan; Min Zhou; Hongzhou Lu; Jieming Qu
Journal:  Am J Respir Crit Care Med       Date:  2020-06-01       Impact factor: 21.405

8.  Long-term coexistence of SARS-CoV-2 with antibody response in COVID-19 patients.

Authors:  Bin Wang; Li Wang; Xianggen Kong; Jin Geng; Di Xiao; Chunhong Ma; Xue-Mei Jiang; Pei-Hui Wang
Journal:  J Med Virol       Date:  2020-05-05       Impact factor: 2.327

9.  Hematologic parameters in patients with COVID-19 infection.

Authors:  Bingwen Eugene Fan; Vanessa Cui Lian Chong; Stephrene Seok Wei Chan; Gek Hsiang Lim; Kian Guan Eric Lim; Guat Bee Tan; Sharavan Sadasiv Mucheli; Ponnudurai Kuperan; Kiat Hoe Ong
Journal:  Am J Hematol       Date:  2020-03-19       Impact factor: 10.047

10.  Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.

Authors:  Fei Zhou; Ting Yu; Ronghui Du; Guohui Fan; Ying Liu; Zhibo Liu; Jie Xiang; Yeming Wang; Bin Song; Xiaoying Gu; Lulu Guan; Yuan Wei; Hui Li; Xudong Wu; Jiuyang Xu; Shengjin Tu; Yi Zhang; Hua Chen; Bin Cao
Journal:  Lancet       Date:  2020-03-11       Impact factor: 79.321

View more
  3 in total

1.  1H qNMR-Based Metabolomics Discrimination of Covid-19 Severity.

Authors:  Banny S B Correia; Vinicius G Ferreira; Priscila M F D Piagge; Mariana B Almeida; Nilson A Assunção; Joyce R S Raimundo; Fernando L A Fonseca; Emanuel Carrilho; Daniel R Cardoso
Journal:  J Proteome Res       Date:  2022-06-08       Impact factor: 5.370

2.  Clinical Effectiveness of Regdanvimab Treatment for Mild-to-Moderate COVID-19: A Retrospective Cohort Study.

Authors:  Young Rock Jang; Yoon Ju Oh; Jin Yong Kim
Journal:  Curr Ther Res Clin Exp       Date:  2022-05-16

3.  Immune modulation as a consequence of SARS-CoV-2 infection.

Authors:  Metin Yusuf Gelmez; Fatma Betul Oktelik; Ilhan Tahrali; Vuslat Yilmaz; Umut Can Kucuksezer; Nilgun Akdeniz; Esin Aktas Cetin; Murat Kose; Cigdem Cinar; Fatma Savran Oguz; Sevgi Besisik; Kaya Koksalan; Ozkan Ozdemir; Naci Senkal; Ahmet Gul; Erdem Tuzun; Gunnur Deniz
Journal:  Front Immunol       Date:  2022-08-30       Impact factor: 8.786

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.